Gainers
Diana Containerships Inc (NASDAQ: DCIX) shares
jumped 90.1 percent to $21.31 on no news. Diana Containerships shares rallied nearly 700 percent on Friday.
TOP SHIPS Inc (NASDAQ: TOPS) shares surged 89.7
percent to $1.37 on no news.
TherapeuticsMD Inc (NASDAQ: TXMD) climbed 52.4
percent to $6.64 after the company reported a plan to resubmit the New Drug Application for TX-004HR. TherapeuticsMD reported a Q3
loss of $0.07 per share on revenue of $4.41 million.
Helios and Matheson Analytics Inc (NASDAQ: HMNY)
shares gained 22.6 percent to $11.83. Helios and Matheson will issue institutional investors $100 million in convertible notes to
pay off $5 million owed to MoviePass and increase its stake with an additional $20 million through a previously reported Investment
Option Agreement.
Tel-Instrument Electronics Corp. (NYSE: TIK) rose
17.7 percent to $2.84.
Reata Pharmaceuticals Inc (NASDAQ: RETA) gained 14
percent to $32.98. Reata reported that Phase 2 CARDINAL study met primary endpoint of change in EGFR at 12 weeks.
Michael Kors Holdings Ltd (NYSE: KORS) climbed 13.8
percent to $54.20 after the company reported better-than-expected results for its second quarter and raised its 2018 forecast.
Basic Energy Services, Inc. (NYSE: BAS) shares rose
12.2 percent to $22.56 on narrower-than-expected Q3 loss.
Vascular Biogenics Ltd (NASDAQ: VBLT) climbed 11.4
percent to $6.85. Nanocarrier signed an exclusive agreement with VBL Therapeutics for VB-111 in Japan.
Cavium Inc (NASDAQ: CAVM) climbed 11.2 percent to
$75.90. Marvell Technology is in advanced talks to merge with Cavium, the Wall Street Journal reported.
Twin Disc, Incorporated (NASDAQ: TWIN) surged 11.1
percent to $ 25.21.
Marvell Technology Group Ltd. (NASDAQ: MRVL)
shares gained 9.1 percent to $20.19. Marvell Technology is in advanced talks to merge with Cavium Inc (NASDAQ: CAVM), the Wall Street Journal reported.
Spring Bank Pharmaceuticals Inc (NASDAQ: SBPH)
shares climbed 8 percent to $17.00. B. Riley initiated coverage on Spring Bank Pharma with a Buy rating and a $30.00 price
target.
Flex Pharma Inc (NASDAQ: FLKS) rose 6.3 percent to
$3.53 as the company posted narrower-than-expected Q3 loss.
Losers
Medical Transcription Billing Corp (NASDAQ: MTBC)
dropped 23.3 percent to $3.06. MTBC reported a Q3 loss of $0.14 per share on sales of $7.51 million.
PAR Technology Corporation (NYSE: PAR) declined 18.3
percent to $ 8.94. PAR Technology is expected to release quarterly results on November 13.
Finjan Holdings, Inc. (NASDAQ: FNJN) shares fell
17.4 percent to $1.73. Finjan is expected to release Q3 results on November 9.
Novogen Limited (ADR) (NASDAQ: NVGN) shares
declined 15.4 percent to $2.39.
Sprint Corp (NYSE: S) dropped 13.7 percent to $5.76 as
T-Mobile and Sprint officially end merger discussions. KeyBanc downgraded Sprint from Sector Weight to Underweight.
Neos Therapeutics Inc (NASDAQ: NEOS) shares fell
13.1 percent to $11.21.
Mesa Laboratories, Inc. (NASDAQ: MLAB) shares
declined 10 percent to $142.04 on weaker-than-expected quarterly results.
Ceragon Networks Ltd (NASDAQ: CRNT) fell 9.6
percent to $1.88. Ceragon reported Q3 earnings of $0.05 per share on sales of $76 million.
Henry Schein, Inc. (NASDAQ: HSIC) dropped 8.9
percent to $70.78 as the company posted downbeat quarterly earnings.
CYANOTECH CORP (NASDAQ: CYAN) shares declined 8.9
percent to $4.42. Cyanotech reported Q2 earnings of $0.08 per share on sales of $8.05 million.
Hydrogenics Corporation (USA) (NASDAQ: HYGS)
shares fell 7.2 percent to $9.70. Hydrogenics reported a Q3 loss of $0.13 per share on sales of $12.2 million.
Gray Television, Inc. (NYSE: GTN) dropped 6.2 percent
to $14.40 on weak quarterly earnings.
Horizon Pharma PLC (NASDAQ: HZNP) shares fell 6
percent to $13.33 as the company posted strong Q3 results and raised its FY17 outlook.
T-Mobile US Inc (NASDAQ: TMUS) shares dropped 5.2
percent to $55.83. T-Mobile and Sprint officially end merger discussions.
AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO) shares
fell 5 percent to $3.05. AVEO Oncology and EUSA Pharma disclosed promising Phase 1 results from the Phase 1/2 TiNivo study of
tivozanib and nivolumab in renal cell carcinoma.
ON Semiconductor Corp (NASDAQ: ON) declined 3.6
percent to $20.88 after the company posted downbeat quarterly earnings.
© 2017 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.